Two Sigma Investments LP Grows Stock Holdings in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

Two Sigma Investments LP grew its holdings in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) by 73.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 73,032 shares of the company’s stock after acquiring an additional 31,002 shares during the period. Two Sigma Investments LP owned about 0.15% of Checkpoint Therapeutics worth $234,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Gladstone Institutional Advisory LLC lifted its stake in shares of Checkpoint Therapeutics by 75.4% in the 4th quarter. Gladstone Institutional Advisory LLC now owns 61,399 shares of the company’s stock valued at $196,000 after purchasing an additional 26,399 shares during the period. PUREfi Wealth LLC acquired a new position in shares of Checkpoint Therapeutics in the 4th quarter valued at $32,000. SBI Securities Co. Ltd. acquired a new position in shares of Checkpoint Therapeutics in the 4th quarter valued at $32,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Checkpoint Therapeutics in the 4th quarter valued at $64,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Checkpoint Therapeutics in the 4th quarter valued at $67,000. 22.00% of the stock is owned by hedge funds and other institutional investors.

Checkpoint Therapeutics Stock Performance

NASDAQ:CKPT opened at $4.26 on Thursday. The company has a fifty day moving average of $4.13 and a two-hundred day moving average of $3.72. The stock has a market capitalization of $370.71 million, a PE ratio of -2.32 and a beta of 1.18. Checkpoint Therapeutics, Inc. has a fifty-two week low of $1.80 and a fifty-two week high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.09). Research analysts forecast that Checkpoint Therapeutics, Inc. will post -0.94 earnings per share for the current year.

Wall Street Analyst Weigh In

CKPT has been the subject of several analyst reports. Lake Street Capital reiterated a “hold” rating and issued a $4.10 target price (down from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th. HC Wainwright reiterated a “neutral” rating and issued a $4.10 target price on shares of Checkpoint Therapeutics in a research note on Tuesday, March 11th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $4.80 target price on shares of Checkpoint Therapeutics in a research note on Monday, March 31st.

Insiders Place Their Bets

In other news, CFO William Garrett Gray sold 12,322 shares of the company’s stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $4.05, for a total transaction of $49,904.10. Following the completion of the sale, the chief financial officer now owns 1,446,322 shares of the company’s stock, valued at $5,857,604.10. This represents a 0.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO James F. Oliviero III sold 15,090 shares of the company’s stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $4.04, for a total transaction of $60,963.60. Following the sale, the chief executive officer now directly owns 3,759,929 shares of the company’s stock, valued at $15,190,113.16. The trade was a 0.40% decrease in their position. The disclosure for this sale can be found here. 2.10% of the stock is currently owned by company insiders.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.